Pulmonary arterial hypertension: pathogenesis and clinical management

T Thenappan, ML Ormiston, JJ Ryan, SL Archer - Bmj, 2018 - bmj.com
Pulmonary hypertension is defined as a resting mean pulmonary artery pressure of 25 mm
Hg or above. This review deals with pulmonary arterial hypertension (PAH), a type of …

Cellular and molecular basis of pulmonary arterial hypertension

NW Morrell, S Adnot, SL Archer, J Dupuis… - Journal of the American …, 2009 - jacc.org
Pulmonary arterial hypertension (PAH) is caused by functional and structural changes in the
pulmonary vasculature, leading to increased pulmonary vascular resistance. The process of …

Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies

SL Archer, EK Weir, MR Wilkins - Circulation, 2010 - Am Heart Assoc
Pulmonary arterial hypertension (PAH) is a syndrome in which pulmonary arterial
obstruction increases pulmonary vascular resistance, which leads to right ventricular (RV) …

Molecular pathogenesis of pulmonary arterial hypertension

M Rabinovitch - The Journal of clinical investigation, 2008 - Am Soc Clin Investig
Recent investigations have suggested that it might be possible to reverse the pathology of
pulmonary arterial hypertension (PAH), a disorder that can be rapidly progressive and fatal …

Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1α-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and …

SL Archer, M Gomberg-Maitland… - American Journal …, 2008 - journals.physiology.org
Pulmonary arterial hypertension (PAH) is a lethal syndrome characterized by vascular
obstruction and right ventricular failure. Although the fundamental cause remains elusive …

Pathogenic mechanisms of pulmonary arterial hypertension

SY Chan, J Loscalzo - Journal of molecular and cellular cardiology, 2008 - Elsevier
Pulmonary arterial hypertension (PAH) is a complex disease that causes significant
morbidity and mortality and is clinically characterized by an increase in pulmonary vascular …

PGC1α-mediated mitofusin-2 deficiency in female rats and humans with pulmonary arterial hypertension

JJ Ryan, G Marsboom, YH Fang, PT Toth… - American journal of …, 2013 - atsjournals.org
Rationale: Pulmonary arterial hypertension (PAH) is a lethal, female-predominant, vascular
disease. Pathologic changes in PA smooth muscle cells (PASMC) include excessive …

Validation of high-resolution echocardiography and magnetic resonance imaging vs. high-fidelity catheterization in experimental pulmonary hypertension

D Urboniene, I Haber, YH Fang… - … of Physiology-Lung …, 2010 - journals.physiology.org
High-frequency echocardiography and high-field-strength magnetic resonance imaging
(MRI) are new noninvasive methods for quantifying pulmonary arterial hypertension (PAH) …

Genomewide RNA expression profiling in lung identifies distinct signatures in idiopathic pulmonary arterial hypertension and secondary pulmonary hypertension

R Rajkumar, K Konishi, TJ Richards… - American Journal …, 2010 - journals.physiology.org
Idiopathic pulmonary arterial hypertension (PAH) is a life-threatening condition
characterized by pulmonary arteriolar remodeling. This investigation aimed to identify genes …

BMP type II receptor as a therapeutic target in pulmonary arterial hypertension

M Orriols, MC Gomez-Puerto, P Ten Dijke - Cellular and Molecular Life …, 2017 - Springer
Pulmonary arterial hypertension (PAH) is a chronic disease characterized by a progressive
elevation in mean pulmonary arterial pressure. This occurs due to abnormal remodeling of …